Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Delayed Data from NSDQ)

$4.19 USD

4.19
1,066,402

+0.24 (6.08%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $4.19 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fiscal fourth-quarter results.

Ardelyx (ARDX) Tumbles Following Deficiencies in Tenapanor NDA

by Zacks Equity Research

The FDA notes deficiencies in the NDA seeking approval for Ardelyx's (ARDX) lead pipeline candidate, tenapanor, as a potential treatment for hyperphosphatemia.

Minerva (NERV) Soars on Promising Schizophrenia Study Data

by Zacks Equity Research

Minerva (NERV) is developing its lead pipeline candidate, roluperidone, in patients with negative symptoms of schizophrenia. Positive data from an extension of previously completed late-stage study boosts investors' sentiment.

Viatris (VTRS) Beats on Q1 Earnings & Sales, Announces Dividend

by Zacks Equity Research

Viatris (VTRS) beats on Q1 earnings while sales surpass expectations. The company announces inaugural quarterly dividend.

Moving Average Crossover Alert: Ironwood Pharmaceuticals (IRWD)

by Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

Ironwood's (IRWD) Q1 Earnings Beat, 2021 Guidance Muted

by Zacks Equity Research

Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. However, outlook for 2021 misses market expectations. Stock down.

Ironwood Pharmaceuticals (IRWD) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of 9.09% and 3.82%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Q1 Earnings Miss, Sales Beat

by Zacks Equity Research

United Therapeutics (UTHR) reports mixed first-quarter 2021 results. Higher sales of Orenitram, Unituxin and Tyvaso offset lower sales of Remodulin and Adcirca.

Deciphera (DCPH) Q1 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Deciphera (DCPH) posts a narrower loss in the first quarter while sales beat on the encouraging uptake of Qinlock.

Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Bausch (BHC) beats on earnings but misses on sales in the first quarter due to the ongoing pandemic.

Esperion (ESPR) Q1 Earnings Miss, Lower Drug Price Hits Sales

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports dismal first-quarter results as it misses estimates for earnings and sales. Stock down.

Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat

by Zacks Equity Research

Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.

Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q1 results.

Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports first-quarter 2021 results.

Will Eylea & Dupixent Drive Regeneron's (REGN) Q1 Earnings?

by Zacks Equity Research

Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports first-quarter 2021 results.

Cambium (CMBM) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Cambium's (CMBM) first-quarter 2021 earnings are likely to have been driven by robust demand for superior broadband connectivity supported by a dynamic business model.

Aviat (AVNW) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Aviat's (AVNW) earnings in third-quarter fiscal 2021 are likely to have benefited from the increasing market traction of its microwave transport product and software offerings.

Is a Beat in Store for T-Mobile (TMUS) This Earnings Season?

by Zacks Equity Research

T-Mobile's (TMUS) revenues in the first quarter of 2021 are likely to have benefited from the Sprint merger and customer growth.

Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Beat in the Cards for Twist (TWS) This Earnings Season?

by Zacks Equity Research

Investors will focus on the top-line and bottom-line numbers when Twist (TWST) reports fiscal second-quarter 2021 results.

Ironwood (IRWD) Up 20.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ironwood (IRWD) Q4 Earnings Beat on Solid Linzess Sales

by Zacks Equity Research

Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter. However, outlook for 2021 misses market expectations.

Ironwood Pharmaceuticals (IRWD) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of 33.33% and 9.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q4 Earnings Expected to Decline

by Zacks Equity Research

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Altimmune (ALT) Begins Phase II Study for Chronic Hepatitis B

by Zacks Equity Research

Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.